By Fineline Cube Gan & Lee Pharmaceuticals (SHA: 603087) announced an out‑licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once‑every‑two‑weeks GLP‑1 receptor agonist (GLP‑1 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.
Deal Overview
| Item | Detail |
|---|---|
| Licensor | Gan & Lee Pharmaceuticals (SHA: 603087) |
| Licensee | Menarini |
| Asset | Bonfaglutide Injection (development code: GZR18) |
| Deal Type | Out‑licensing agreement |
| Licensed Territory | 39 European countries and regions |
| Licensee Responsibilities | Regulatory filing and commercialization |
| Announcement Date | 10 Aug 2026 |
Financial Terms
| Component | Value |
|---|---|
| Upfront Payment | EUR 62 million |
| Potential Milestone Payments | Up to EUR 664 million |
| Total Potential Deal Value | Up to EUR 726 million (excluding royalties) |
| Royalties | Tiered double‑digit royalties on net product sales in the licensed territory |
Licensed Territory
Menarini will be responsible for regulatory filing and commercialization of Bonfaglutide in 39 European countries and regions, including:
- The 27 EU member states
- The UK
- Switzerland, Norway, Iceland, Liechtenstein
- The Balkan region
Drug Profile – Bonfaglutide (GZR18)
| Attribute | Detail |
|---|---|
| Molecule | Bonfaglutide Injection (GZR18) |
| Class | Novel glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA) |
| Dosing | Once‑every‑two‑weeks administration |
| Origin | Independently developed by Gan & Lee |
| Category | Category 1 innovative drug |
| Indications | Obesity/overweight, type 2 diabetes mellitus (T2DM), and other metabolic diseases |
Clinical Evidence
| Trial | Indication | Region | Outcome |
|---|---|---|---|
| Pivotal Phase 3 | Weight management in obesity and overweight | China | Primary endpoints met |
| Phase 2 | Weight management in obesity and overweight | United States | Primary endpoints met |
Competitive Differentiation
Compared with traditional weekly GLP‑1 RA formulations, Bonfaglutide reduces injection frequency by approximately 50% — a meaningful convenience advantage that could improve patient adherence in chronic weight management and diabetes treatment.
Strategic Rationale & Market Impact
- Differentiated Dosing in a Crowded Field: In the intensely competitive GLP‑1 RA market, Bonfaglutide’s once‑every‑two‑weeks dosing offers a clear differentiator against weekly incumbents, potentially capturing patients who prioritize injection convenience.
- Europe‑Wide Scale: Licensing across 39 countries and regions — including all 27 EU member states — gives Bonfaglutide one of the broadest European footprints for a China‑origin GLP‑1 asset, executed through Menarini’s established European commercial infrastructure.
- De‑Risked Asset: With primary endpoints already met in both a pivotal Phase 3 trial in China and a Phase 2 trial in the US, the asset enters the partnership with validated clinical efficacy across two major regulatory jurisdictions.
- Value Realization for Gan & Lee: The EUR 726 million potential deal value plus tiered double‑digit royalties represents significant monetization of Gan & Lee’s independently developed metabolic franchise while retaining upside in its home market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Bonfaglutide’s regulatory filings, milestone achievement, and commercial performance in Europe. Actual results may differ due to risks including regulatory decisions, market adoption, and competitive dynamics in the GLP‑1 RA class.-Fineline Info & Tech